There are many opportunities for Nephrology fellows to participate in research at EVMS.
My laboratory within the Division of Nephrology in the Eastern Virginia Medical School is dedicated on researches to discover new diagnostic markers and novel therapies for patients with kidney disease. Being a nephrologist seeing patients with all kinds of kidney disease, I have always had a unique perspective to biomedical research that is inspired by my personal experience in caring for patients. I hope my research work can help to discover new therapies for my patient’s devastating diseases. There are currently two research field in my laboratory. One is polycystic kidney disease and the other one is diabetic nephropathy.
Polycystic kidney disease is a genetic disorder characterized by the growth of numerous cysts in the kidneys. Polycystic kidney disease cysts can profoundly enlarge the kidneys while replacing much of the normal structure, resulting in reduced kidney function and leading to kidney failure. A common complication of polycystic kidney disease is high blood pressure. Kidney failure is another common problem for people with polycystic kidney disease.
Jerry L. Nadler, MD, FACP, FAHA, FACE, is Professor and the Harry H. Mansbach Endowed Chair in Internal Medicine and Vice Dean of Research. Dr. Nadler had been Director of the Strelitz Diabetes Center (SDC) at EVMS but he stepped down from that post in the fall of 2013 to devote time to his new added role overseeing research at EVMS. He remains a key member of the SDC team.
Dr. Nadler has been a member of a Special Advisory Committee on Type I Diabetes with the Director of the National Institutes of Health (NIH). He has research funding from the NIH as well as the Juvenile Diabetes Foundation. Dr. Nadler has been a standing member of the ADA, American Heart, and NIH grant review committees. He has over 190 peer-reviewed publications in major scientific Journals in the field. He also has been an invited speaker at the American Diabetes Association, Australian Diabetes Association, World Diabetes Congress and International Meetings of the European Association of Diabetes.
His primary interest is the role of lipid and immune inflammatory pathways leading to pancreatic beta cell damage and better understanding of the cardiovascular complications of diabetes and obesity. He is also very active in developing new therapies to help prevent inflammatory damage to pancreatic islets and stopping the complications of diabetes. He holds 11 patents and has been involved in biotech start-up companies.